E Fund Management Co. Ltd. Buys 6,171 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

E Fund Management Co. Ltd. raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 17.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,548 shares of the biopharmaceutical company’s stock after purchasing an additional 6,171 shares during the period. E Fund Management Co. Ltd.’s holdings in Amicus Therapeutics were worth $604,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of FOLD. Van ECK Associates Corp raised its position in shares of Amicus Therapeutics by 23.1% during the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 873 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Amicus Therapeutics by 97.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,368 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 3,638 shares in the last quarter. Park Avenue Securities LLC bought a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $128,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $134,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $158,000.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares in the company, valued at $12,197,066. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at $12,197,066. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Michael Clark sold 4,427 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $61,978.00. Following the completion of the transaction, the insider now owns 253,664 shares of the company’s stock, valued at approximately $3,551,296. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,208 shares of company stock worth $732,930. 2.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on FOLD shares. JPMorgan Chase & Co. reduced their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, March 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.28 during trading hours on Wednesday, reaching $10.14. The company had a trading volume of 2,242,432 shares, compared to its average volume of 2,969,459. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42. The stock has a 50-day moving average of $11.35 and a two-hundred day moving average of $11.98. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57. The firm has a market capitalization of $3.00 billion, a PE ratio of -19.88 and a beta of 0.80.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The firm had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. Analysts forecast that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.